Fungal Infections in Neonatal Intensive Care, An Overview
Life Sciences-Neonatal Fungal Infection
DOI:
https://doi.org/10.22376/ijpbs/lpr.2022.12.6.SP24.L17-28Keywords:
Neonates, ICU, Fungal Infection, NICU, FungusAbstract
fungal infections in immature newborns have become more common in the previous two decades, especially when they are admitted to a Neonatal Intensive Care Unit (NICU). Thus, it is projected that the mortality rate of children under the age of five is estimated to be about 6 million children a year, with even about 40% of these mortalities during the newborn period. Considering the increased prevalence of death rates related to invasive fungal infections, proper preventative medication is still critical in their treatment. The proper utilization antifungals medicines are critical in the primary prevention and management of invasive fungal infection in newborns; however, there are no specific guidelines to determine the proper medication selection. The most appropriate cure of fungal infection in this population necessitates extensive research into the pharmacokinetic, tolerability, and effectiveness of antifungal medicines. This paper aims to overview epidemiology, diagnosis and management of neonatal fungal infections.Children's invasive fungal infections appear to have become more common during the previous few decades. Children with primary and secondary immunodeficiencies are at danger, as well as newborns. The most often isolated microbes are Candida and Aspergillus species. Improved outcomes depend on prompt diagnosis and administration of the proper antifungal medication. Traditional methods take a lot of time, and obtaining relevant sample material in a paediatric setting may require intrusive procedures. The improvements in detection and quick species identification are summarised in this paper. In light of the antifungal spectrum of the available drugs and the distinct pharmacokinetic features in various age groups, the current antifungal therapy options for newborns and kids are next examined.
References
Kaufman DA. Challenging issues in neonatal candidiasis. Curr Med Res Opin. 2010;26(7):1769-1778.
Bersani I, Piersigilli F, Goffredo BM, et al. Antifungal Drugs for Invasive Candida Infections (ICI) in Neonates: Future Perspectives. Front Pediatr. 2019;7:375. Published 2019 Sep 20.
Montagna MT, Lovero G, De Giglio O, et al. Invasive fungal infections in neonatal intensive care units of Southern Italy: a multicentre regional active surveillance (AURORA project). J Prev Med Hyg. 2010;51(3):125-130.
Smith ER, Bergelson I, Constantian S, Valsangkar B, Chan GJ. Barriers and enablers of health system adoption of kangaroo mother care: a systematic review of caregiver perspectives. BMC Pediatr. 2017;17(1):35. Published 2017 Jan 25.
Chitnis AS, Magill SS, Edwards JR, Chiller TM, Fridkin SK, Lessa FC. Trends in Candida central line-associated bloodstream infections among NICUs, 1999-2009. Pediatrics. 2012;130(1):46-52.
KAUFMAN, D. A. “Getting to zero”: preventing invasive Candida infections and eliminating infection-related mortality and morbidity in extremely preterm infants. Early Human Development, 2012, 88: S45-S49.
Caggiano G, Lovero G, De Giglio O, et al. Candidemia in the Neonatal Intensive Care Unit: A Retrospective, Observational Survey and Analysis of Literature Data. Biomed Res Int. 2017;2017:7901763.
Kelly MS, Benjamin DK Jr, Smith PB. The epidemiology and diagnosis of invasive candidiasis among premature infants. Clin Perinatol. 2015;42(1):105-ix.
Testoni D, Smith PB, Benjamin DK Jr. The use of antifungal therapy in neonatal intensive care. Clin Perinatol. 2012;39(1):83-98.
Wu Y, Wang J, Li W, et al. Pichia fabianii blood infection in a premature infant in China: case report. BMC Res Notes. 2013;6:77. Published 2013 Mar 4
Goel S, Mittal S, Chaudhary U. Role of Non Albicans Candida Spp. and Biofilm in Neonatal ICU. Infect Disord Drug Targets. 2016;16(3):192-198.
Zhou M, Li Y, Kudinha T, Xu Y, Liu Z. Kodamaea ohmeri as an Emerging Human Pathogen: A Review and Update. Front Microbiol. 2021;12:736582. Published 2021 Sep 10.
De Rose DU, Santisi A, Ronchetti MP, et al. Invasive Candida Infections in Neonates after Major Surgery: Current Evidence and New Directions. Pathogens. 2021;10(3):319. Published 2021 Mar 9.
Driessen M, Ellis JB, Cooper PA, et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J. 1996;15(12):1107-1112.
Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110(2 Pt 1):285-291.
Clerihew L, Lamagni TL, Brocklehurst P, McGuire W. Invasive fungal infection in very low birthweight infants: national prospective surveillance study. Arch Dis Child Fetal Neonatal Ed. 2006;91(3):F188-F192.
Chapman RL. Candida infections in the neonate. Curr Opin Pediatr. 2003;15(1):97-102.
Huang YC, Li CC, Lin TY, et al. Association of fungal colonization and invasive disease in very low birth weight infants. Pediatr Infect Dis J. 1998;17(9):819-822.
Baley JE, Kliegman RM, Boxerbaum B, Fanaroff AA. Fungal colonization in the very low birth weight infant. Pediatrics. 1986;78(2):225-232.
Tripathi N, Watt K, Benjamin DK Jr. Treatment and prophylaxis of invasive candidiasis. Semin Perinatol. 2012;36(6):416-423.
Long SS, Stevenson DK. Reducing Candida infections during neonatal intensive care: management choices, infection control, and fluconazole prophylaxis. J Pediatr. 2005;147(2):135-141.
Karlowicz MG, Hashimoto LN, Kelly RE Jr, Buescher ES. Should central venous catheters be removed as soon as candidemia is detected in neonates?. Pediatrics. 2000;106(5):E63.
Diamond RD, Krzesicki R, Jao W. Damage to pseudohyphal forms of Candida albicans by neutrophils in the absence of serum in vitro. J Clin Invest. 1978;61(2):349-359.
Kaufman D, Fairchild KD. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev. 2004;17(3):638-680.
Schultz C, Temming P, Bucsky P, Göpel W, Strunk T, Härtel C. Immature anti-inflammatory response in neonates. Clin Exp Immunol. 2004;135(1):130-136.
Benjamin DK Jr, Ross K, McKinney RE Jr, Benjamin DK, Auten R, Fisher RG. When to suspect fungal infection in neonates: A clinical comparison of Candida albicans and Candida parapsilosis fungemia with coagulase-negative staphylococcal bacteremia. Pediatrics. 2000;106(4):712-718.
Chapman RL. Candida infections in the neonate. Curr Opin Pediatr. 2003;15(1):97-102.
Benjamin DK Jr, Stoll BJ, Gantz MG, et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics. 2010;126(4):e865-e873.
Shane AL, Stoll BJ. Neonatal sepsis: progress towards improved outcomes. J Infect. 2014;68 Suppl 1:S24-S32.
Bougnoux ME, Kac G, Aegerter P, d'Enfert C, Fagon JY; CandiRea Study Group. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med. 2008;34(2):292-299.
Brady MT. Health care-associated infections in the neonatal intensive care unit. Am J Infect Control. 2005;33(5):268-275.
Devlin RK. Invasive fungal infections caused by Candida and Malassezia species in the neonatal intensive care unit. Adv Neonatal Care. 2006;6(2):68-79.
Aliaga S, Clark RH, Laughon M, et al. Changes in the incidence of candidiasis in neonatal intensive care units. Pediatrics. 2014;133(2):236-242.
Huang YC, Lin TY, Lien RI, et al. Candidaemia in special care nurseries: comparison of albicans and parapsilosis infection. J Infect. 2000;40(2):171-175.
Lupetti A, Tavanti A, Davini P, et al. Horizontal transmission of Candida parapsilosis candidemia in a neonatal intensive care unit. J Clin Microbiol. 2002;40(7):2363-2369.
Fridkin SK, Kaufman D, Edwards JR, Shetty S, Horan T. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics. 2006;117(5):1680-1687.
Finkelstein R, Reinhertz G, Hashman N, Merzbach D. Outbreak of Candida tropicalis fungemia in a neonatal intensive care unit. Infect Control Hosp Epidemiol. 1993;14(10):587-590.
Chryssanthou E, Broberger U, Petrini B. Malassezia pachydermatis fungaemia in a neonatal intensive care unit. Acta Paediatr. 2001;90(3):323-327.
Garey KW ,Rege M ,Pai MP et al.Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.Clin Infect Dis. 2006; 43: 25-31
Morrell M ,Fraser VJ, Kollef MH Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.
Lass-Florl C ,Resch G ,Nachbaur D et al.The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients.
Ruchel R Margraf S Rapid microscopical diagnosis of deep-seated mycoses following maceration of fresh specimens and staining with optical brighteners. Mycoses. 1993; 36: 239-242
Ruchel R ,Schaffrinski M Versatile fluorescent staining of fungi in clinical specimens by using the optical brightener Blankophor.J Clin Microbiol. 1999; 37: 2694-2696 Clin Infect Dis. 2007; 45: e101-e104 Antimicrob Agents Chemother. 2005; 49: 3640-3645
Forrest GN ,Mankes K ,Jabra-Rizk MA et al.Peptide nucleic acid fluorescence in situ hybridization-based identification of Candida albicans and its impact on mortality and antifungal therapy costs. J Clin Microbiol. 2006; 44: 3381-3383
Rigby S ,Procop GW ,Haase G et al.Fluorescence in situ hybridization with peptide nucleic acid probes for rapid identification of Candida albicans directly from blood culture bottles. J Clin Microbiol. 2002; 40: 2182-2186
Shepard JR ,Addison RM ,Alexander BD et al.Multicenter evaluation of the Candida albicans/Candida glabrata peptide nucleic acid fluorescent in situ hybridization method for simultaneous dual-color identification of C. albicans and C. glabrata directly from blood culture bottles.J Clin Microbiol. 2008; 46: 50-55
Trnovsky J ,Merz W ,Della-Latta P ,Wu F ,Arendrup MC ,Stender H Rapid and accurate identification of Candida albicans isolates by use of PNA FISHFlow.J Clin Microbiol. 2008; 46: 1537-1540
Almirante B ,Rodriguez D ,Park BJ et al.Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003.J Clin Microbiol. 2005; 43: 1829-1835
Chen S ,Slavin M ,Nguyen Q et al.Active surveillance for candidemia, Australia.Emerg Infect Dis. 2006; 12: 1508-1516
Hajjeh RA ,Sofair AN ,Harrison LH et al.Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program.J Clin Microbiol. 2004; 42: 1519-1527
Sandven P ,Bevanger L ,Digranes A ,Haukland HH ,Mannsaker T ,Gaustad P Candidemia in Norway (1991 to 2003): results from a nationwide study.J Clin Microbiol. 2006; 44: 1977-1981
Chryssanthou E ,Fernandez V ,Petrini B Performance of commercial latex agglutination tests for the differentiation of Candida dubliniensis and Candida albicans in routine diagnostics.Apmis. 2007; 115: 1281-1284
Freydiere AM ,Buchaille L ,Guinet R ,Gille Y Evaluation of latex reagents for rapid identification of Candida albicans and C. krusei colonies.J Clin Microbiol. 1997; 35: 877-880
Marot-Leblond A ,Beucher B ,David S ,Nail-Billaud S ,Robert R Development and evaluation of a rapid latex agglutination test using a monoclonal antibody to identify Candida dubliniensis colonies.J Clin Microbiol. 2006; 44: 138-142
Freydiere AM,Perry JD,Faure O et al.Routine use of a commercial test, GLABRATA RTT, for rapid identification of Candida glabrata in six laboratories.J Clin Microbiol. 2004; 42: 4870-4872
Freydiere AM ,Robert R ,Ploton C ,Marot-Leblond A ,Monerau F ,Vandenesch F Rapid identification of Candida glabrata with a new commercial test, GLABRATA RTT.J Clin Microbiol. 2003; 41: 3861-3863
Willinger B ,Wein S ,Hirschl AM ,Rotter ML ,Manafi M Comparison of a new commercial test, GLABRATA RTT, with a dipstick test for rapid identification of Candida glabrata.J Clin Microbiol. 2005; 43: 499-501
Hovi L ,Saxen H ,Saarinen-Pihkala UM ,Vettenranta K ,Meri T ,Richardson M Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders.Pediatr Blood Cancer. 2007; 48: 28-34
Miceli MH ,Grazziutti ML ,Woods G et al. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications.Clin Infect Dis. 2008; 46: 1412-1422
Rohrlich P,Sarfati J,Mariani P et al. Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis.Pediatr Infect Dis J. 1996; 15: 232-237
Steinbach WJ,Addison RM,McLaughlin L et al.Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients.Pediatr Infect Dis J. 2007; 26: 558-564
Sulahian A,Boutboul F,Ribaud P,Leblanc T,Lacroix C,Derouin F Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study.Cancer. 2001; 91: 311-318
Herbrecht R,Letscher-Bru V,Oprea C et al.Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients.J Clin Oncol. 2002; 20: 1898-1906
nnink-Kersten MA,Klont RR,Warris A,Op denCamp HJ,Verweij PE Bifidobacterium lipoteichoic acid and false ELISA reactivity in Aspergillus antigen detection.Lancet. 2004; 363: 325-327
Mennink-Kersten MA,Ruegebrink D,Klont RR et al.Bifidobacterial lipoglycan as a new cause for false-positive platelia Aspergillus enzyme-linked immunosorbent assay reactivity.J Clin Microbiol. 2005; 43: 3925-3931
Mens H,Hojlyng N,Arendrup MC Disseminated Penicillium marneffei sepsis in a HIV-positive Thai woman in Denmark.Scand J Infect Dis. 2004; 36: 507-509
Wheat LJ,Hackett E,Durkin M et al.Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay.Clin Vaccine Immunol. 2007; 14: 638-640
Clancy CJ,Jaber RA,Leather HL et al.Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients.J Clin Microbiol. 2007; 45: 1759-1765
Husain S,Clancy CJ,Nguyen MH et al.Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid.Clin Vaccine Immunol. 2008; 15: 1760-1763
Christensson B,Wiebe T,Pehrson C,Larsson L Diagnosis of invasive candidiasis in neutropenic children with cancer by determination of D-arabinitol/L-arabinitol ratios in urine.J Clin Microbiol. 1997; 35: 636-640
Walsh TJ,Merz WG,Lee JW et al.Diagnosis and therapeutic monitoring of invasive candidiasis by rapid enzymatic detection of serum D-arabinitol.Am J Med. 1995; 99: 164-172
Sigmundsdottir G,Christensson B,Bjorklund LJ,Hakansson K,Pehrson C,Larsson L Urine D-arabinitol/L-arabinitol ratio in diagnosis of invasive candidiasis in newborn infants.J Clin Microbiol. 2000; 38: 3039-3042
Lehtonen L,Rantala A,Oksman P,Eerola E,Lehtonen OP Determination of serum arabinitol levels by mass spectrometry in patients with postoperative candidiasis.Eur J Clin Microbiol Infect Dis. 1993; 12: 330-335
Lamagni TL, Evans BG, Shigematsu M,et al. Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990 -- 9).Epidemiol Infect 2001;126:397-414
Bendel CM. Candidiasis. In:Remington JS, Klein JO, Wilson CB,Baker CJ, editors. Infectious diseases of the fetus and newborn infant. 6th edition. Elsevier Saunders; Philadelphia:2006. p. 1107-28
Pappas PG, Rex JH, Lee J, et al.A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.Clin Infect Dis 2003;37:634-43
Benjamin DK Jr, Stoll BJ. Infection in late preterm infants. Clin Perinatol 2006;33:871-82
Wisplinghoff H, Bischoff T,Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17
Dornbusch HJ, Manzoni P, Roilides E,et al. Invasive fungal infections in children. Pediatr Infect Dis J 2009;28:734-7
Lopez Sastre JB, Coto Cotallo GD,Fernandez CB. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol 2003;20:153-63
Baley JE, Kliegman RM, Fanaroff AA: Disseminated fungal infections in very low- birth-weight infants: Clinical manifestations and epidemiology. Pediatrics 73:144-152,1984
Faix RG: Systemic Candida infections in infants in intensive care nurseries: High incidence of central nervous system involvement. J Pediatr 105:616-622, 1984
Johnson DE, Thompson TR, Green TP, et al: Systemic candidiasis in very low-birth-weight infants ( 1500 grams). Pediatrics 73:138-143, 1984
Stoll BJ, Gordon T, Korones SB, et al: Late-onset sepsis in very low birth weight neonates: A report from the National nstitute of Child Health and Human Development Neonatal Research Network. J Pediatr 29:63-71,1996
Fanaroff AA, Korones SB, Wright LL, et al: Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. The National Institute of Child Health and Human Development Neonatal Research Network. Pediatr Infect Dis J 17:593-598, 1998
Kossoff EH, Buescher ES, Karlowicz MG: Candidemia in a neonatal intensive care unit: Trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J 17:504-508, 1998
Mittal M, Dhanireddy R, Higgins RD: Candida sepsis and association with retinopathy of prematurity. Pediatrics 101:654-657, 1998
Saiman L, Ludington E, Pfaller M, et al: Risk factors for candidemia in neonatal intensive care unit patients. Pediatr Infect Dis J 19:319-324, 2000
Makhoul IR, Kassis I, Smolkin T, et al: Review of 49 infants with acquired fungal sepsis: further characterization. Pediatrics 107:61-66, 2001
Stoll BJ, Hansen N, Fanaroff AA, et al: Late-onset sepsis in very low birth weight neonates: The experience of the NICHD Neonatal Research Network. Pediatrics 110:285-291, 2002
Faix RG: Invasive neonatal candidiasis: Comparison of albicans and parapsilosis infection. Pediatr Infect Dis J 11:88-93, 1992
Pfaller MA, Diekema DJ, Jones RN, et al: Trends in antifungal susceptibility of candida spp. isolated from pediatric and adult patients with bloodstream infections: Sentry antimicrobial surveillance program, 1997 to 2000. J Clin Microbiol 40:852-856, 2002
Hostetter MK: New insights into candidal infections. Adv Pediatr 43:209-230, 1996
Ruderman JW: A clue (tip-off) to urinary infection with Candida. Pediatr Infect Dis J 9:586-588, 1990
Yadin O, Gradus Ben-Ezer D, Golan A, et al: Survival of a premature neonate with obstructive anuria due to Candida: The role of early sonographic diagnosis and antimycotic treatment. Eur J Pediatr 147:653-655, 1988
Winters WD, Shaw DW, Weinberger E: Candida fungusballs presenting as intraventricular masses in cranial sonography. J Clin Ultrasound 23:266-270, 1995
Rowen JL, Atkins JT, Levy ML, et al: Invasive fungal dermatitis in the or 1000-gram neonate. Pediatrics 95:682-687, 1995
Chapman RL, Faix RG: Persistently positive cultures and outcome in invasive neonatal candidiasis. Pediatr Infect Dis J 19:822-827, 2000
Steinbach WJ. Pediatric aspergillosis: disease and treatment differences in children. Pediatr Infect Dis J 2005;24:358-64
Steinbach WJ. Invasive aspergillosis in pediatric patients. Curr Med Res Opin 2010;26:1779-87
Groll AH, Jaeger G, Allendorf A, et al. Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first 3 months of life. Clin Infect Dis 1998;27:437-52
Robertson AF, Joshi VV, Ellison DA, et al. Zygomycosis in neonates. Pediatr Infect Dis J 1997;16:812-15
Kaufman D. Fungal infection in the very low birthweight infant. Curr Opin Infect Dis 2004;17:253-9
Roilides E, Zaoutis TE, Katragkou A, et al. Zygomycosis in neonates: an uncommon but life-threatening infection. Am J Perinatol 2009;26:565-73
Manzoni P, Farina D, Leonessa M, et al. Risk factors for progression to invasive fungal infection in preterm neonates with fungal colonization. Pediatrics 2006;118:2359-64
Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in neonatal intensive care unit patients: the National Epidemiology of Mycosis Survey Study Group. Pediatr Infect Dis J 2000;19:319-24
Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J. 1998;17(6):504-508.
Beck-Sague CM, Azimi P, Fonseca SN, et al. Bloodstream infections in neonatal intensive care unit patients: results of a multicenter study. Pediatr Infect Dis J. 1994;13(12):1110-1116.
Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA et al. Late-onset sepsis in very low birth weight neonates: The experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110(2):285-291.
Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982;72(1):101-111.
Mennink-Kersten MA, Verweij PE. Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am 2006;20:711-27
Pappas PG,Kauffman CA ,Andes D et al.Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48: 503-535
Walsh TJ,Anaissie EJ ,Denning DW et al.Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46: 327-360
Fisher BT,Zaoutis TE Treatment of invasive candidiasis in immunocompromised pediatric patients. Paediatr Drugs. 2008; 10: 281-298
Burgos A,Zaoutis TE,Dvorak CC et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics. 2008; 121: e1286-e1294
Walsh TJ,Anaissie EJ,Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46: 327-360
Herbrecht R,Denning DW,Patterson TF et al.Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.N Engl J Med. 2002; 347: 408-415
Cornely OA,Maertens J,Bresnik M et al.Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBi-Load trial).Clin Infect Dis. 2007; 44: 1289-1297
Kobayashi S,Murayama S,Takanashi S et al. Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in Japan. Eur J Pediatr. 2008; 167: 1389-1394
Andes D,Pascual A,Marchetti O Antifungal therapeutic drug monitoring: established and emerging indications.Antimicrob Agents Chemother. 2009; 53: 24-34
Krishna G,Sansone-Parsons A,Martinho M,Kantesaria B,Pedicone L Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.Antimicrob Agents Chemother. 2007; 51: 812-818
Karlsson MO,Lutsar I,Milligan PA A population pharmacokinetic analysis of Voriconazole plasma concentration data from pediatric studies.Antimicrob Agents Chemother. 2009; 53: 935-944
Walsh TJ,Karlsson MO,Driscoll T et al.Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.Antimicrob Agents Chemother. 2004; 48: 2166-2172
Hennig S,Wainwright CE,Bell SC,Miller H,Friberg LE,Charles BG Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.Clin Pharmacokinet. 2006; 45: 1099-1114
Pemán J, Cantón E, Linares-Sicilia MJ, et al. Epidemiology and antifungal susceptibility of bloodstream fungal isolates in pediatric patients: a Spanish multicenter prospective survey. J Clin Microbiol. 2011;49(12):4158-4163.
Blyth CC, Chen SC, Slavin MA, et al. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics. 2009;123(5):1360-1368.
Ericson J, Manzoni P, Benjamin DK Jr. Old and new: appropriate dosing for neonatal antifungal drugs in the nursery. Early Hum Dev. 2013;89 Suppl 1(0 1):S25-S27.
Hassan, Mahmuda & Yasmeen, B H & Begum, Nasreen. (2015). Fungal sepsis and Indications of antifungal prophylaxis and treatment in neonatal intensive care units : A review. Northern International Medical College Journal. 6. 6. 10.3329/nimcj.v6i1.23150.
Pana ZD, Kougia V, Roilides E. Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients: an update. Expert Opin Pharmacother. 2015;16(5):693-710.
Lestner JM, Versporten A, Doerholt K, et al. Systemic antifungal prescribing in neonates and children: outcomes from the Antibiotic Resistance and Prescribing in European Children (ARPEC) Study. Antimicrob Agents Chemother. 2015;59(2):782-789.
Hope WW, Castagnola E, Groll AH, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect. 2012;18 Suppl 7:38-52.
Leroux S, Jacqz-Aigrain E, Elie V, et al. Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial. Br J Clin Pharmacol. 2018;84(9):1989-1999.
Thompson GR III, Cadena J, Patterson TF. Overview of antifungal agents. Clin Chest Med 2009;30:203-15 Manzoni P, Mostert M, Castagnola E. Update on the management of Candida infections in preterm neonates. Arch Dis Child Fetal Neonatal Ed. 2015;100(5):F454-F459. doi:10.1136/archdischild-2012-303350
Chapman RL. Prevention and treatment of Candida infections in neonates.Semin Perinatol 2007;31:39-46
Almirante B, Rodriguez D. Antifungal agents in neonates: issues and recommendations. Paediatr Drugs 2007;9:311-21
Pappas PG, Kauffman CA, Andes D,et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis:2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-35
Smith PB, Steinbach WJ,Benjamin DK Jr. Neonatal candidiasis. Infect Dis Clin North Am2005;19:603-15
Steinbach WJ. Antifungal agents in children. Pediatr Clin North Am2005;52:895-915
Friedman S, Richardson SE, Jacobs SE,et al. Systemic candida infection in extremely low birth weight infants: short term morbidity and long-term neurodevelopmental outcome.Pediatr Infect Dis J 2000;19:499-504
Pappas PG, Rex JH, Sobel JD, et al.Guidelines for treatment of candidiasis.Clin Infect Dis 2004;38:161-89
Linder N, Klinger G, Shalit I, et al.Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations.J Antimicrob Chemother 2003;52:663-7
Driessen M, Ellis JB, Cooper PA, et al.Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial.Pediatr Infect Dis J 1996;15:1107-12
Steinbach WJ. Pediatric aspergillosis:disease and treatment differences in children. Pediatr Infect Dis J2005;24:358-64
Roilides E, Zaoutis TE, Katragkou A,et al. Zygomycosis in neonates:an uncommon but life-threatening infection. Am J Perinatol 2009;26:565-73
Smolinski KN, Shah SS, Honig PJ, et al.Neonatal cutaneous fungal infections. Curr Opin Pediatr 2005;17:486-93
Kwon DS, Mylonakis E. Posaconazole: a new broadspectrum antifungal agent. Expert Opin Pharmacother2007;8:1167-78
Groll AH, Jaeger G, Allendorf A, et al. Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first three months of life. Clin Infect Dis 1998;27:437-52
Shane AL, Stoll BJ. Recent developments and current issues in the epidemiology, diagnosis, and management of bacterial and fungal neonatal sepsis. Am J Perinatol. 2013;30(2):131-141.
Watt K, Manzoni P, Cohen-Wolkowiez M, et al. Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole. Curr Drug Metab. 2013;14(2):193-202.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Nazim Faisal Hamid, Naif Mutkhan Alsharari, Abdulrahman Abdullah Aloufi, Mustafa M Altoonisi, Saad Abdullah Alamri, Khalid Hashim Alanazi, Abdullah Ahmad Alatawi, Ghalib Mohammed Alsulami, Hamzah Amer Alshahrani , Nawaf Hussain Hamdi, Bakr Akram Sayfi Jalawi

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.